MENA's MASLD Fight Offers Global Insights for Liver Care

Top Summary

• What happened: A new report highlights the significant challenges in managing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Middle East and North Africa (MENA) region.
• Why it matters: The MENA region's experience with high disease burden and variable resources offers crucial, transferable insights for managing MASLD globally, including in Europe.
• What changes: Understanding these challenges can lead to improved awareness, diagnostic strategies, pharmacotherapy access, and care coordination for MASLD patients worldwide.
• Who is affected: Approximately one in three adults globally suffer from MASLD, making this a widespread health concern impacting patients, clinicians, and policymakers.

MENA Region Grapples with High MASLD Burden

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a growing global health crisis, affecting nearly one in three adults worldwide. The Middle East and North Africa (MENA) region faces a particularly high burden of this condition.

MASLD prevalence in MENA is reported between 36-46%, with countries like Egypt, Kuwait, and Qatar showing the highest rates. This surge is linked to widespread obesity and Type 2 diabetes.

Accelerated Disease Progression and Knowledge Gaps

A concerning trend in the MENA region is the earlier onset of hepatic fibrosis and a faster progression from MASLD to more severe forms like MASH. This is attributed to a dense clustering of metabolic risk factors among patients.

Furthermore, a significant knowledge gap among physicians regarding MASLD identification, diagnosis, and management has been identified. This deficit is most pronounced in primary care, with guideline adherence rates as low as 38-51%.

Challenging Care Settings Defined

The report defines a 'challenging care setting' as a clinical environment where MASLD care is hampered by structural barriers. These barriers are not unique to the MENA region but are increasingly relevant in various healthcare systems.

Key challenges include fragmented referral pathways, limited primary care preparedness, restricted access to advanced diagnostics, delayed fibrosis staging, and insufficient multidisciplinary coordination.

Four Pillars of MASLD Management

The authors identify four critical pillars for effective MASLD management in these challenging settings, offering transferable lessons:

• Awareness and Education Gaps: Addressing the deficit in knowledge among healthcare professionals.
• Diagnostic Access and Risk Stratification: Improving access to and use of non-invasive diagnostic tools.
• Pharmacotherapy Affordability and Access: Ensuring equitable access to emerging treatments.
• Care Coordination: Enhancing collaboration across fragmented health systems.

Global Relevance of MENA's Experience

The MENA region's experience, with its high disease burden and variable resources, provides a practical lens for understanding implementation challenges. These insights are directly applicable to clinicians and policymakers in other regions, including Europe.

By examining the MENA's successes and hurdles, other health systems can proactively address similar issues as MASLD prevalence rises. This includes strengthening primary care's role and optimizing diagnostic and treatment pathways.

What to Watch Next

Future developments will likely focus on strategies to bridge the identified knowledge gaps through targeted educational programs. Efforts to improve access to affordable non-invasive diagnostic tools and emerging pharmacotherapies are also anticipated to gain momentum globally.